Ocugen, Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced the dosing of the first patient in its Phase 2/3 GARDian3 pivotal confirmatory trial for OCU410ST. This novel modifier gene therapy candidate is being developed to treat Stargardt disease (ABCA4-associated retinopathies). The clinical study will enroll 51 participants, with 34 receiving a one-time subretinal injection of the therapy, while 17 will be part of an untreated control group. The trial's primary objective is to assess the reduction in atrophic lesion size, with secondary endpoints focused on improvements in best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA). Results from the one-year follow-up are expected to support Ocugen's planned Biologics License Application $(BLA.SI)$ submission in 2027. No results from the trial have been presented yet.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.